{ "items": [ "\n\n
Application form to request data sharing
\n \n\n \n\n \n \n 2-dataapplicationformv3-16nov2018-1.docx\n (21 KB)\n \n
\n \n \n \n \nMedical Product Quality Report COVID-19 VACCINE issues. Up to 31 May 2021
\n \n\n \n\n \n \n Medical Product Quality Report_COVID-19 VACCINE issues_Up to 31May2021.pdf\n (1 MB)\n \n
\n \n \n \n \nMedical Product Quality Report COVID-19 VACCINE issues. Up to 30 April 2021
\n \n\n \n\n \n \n Medical Product Quality Report_COVID-19 VACCINE issues_Up to 30April2021.pdf\n (1 MB)\n \n
\n \n \n \n \nMedical Product Quality Report COVID-19 VACCINE issues.Up to 31 March 2021
\n \n\n \n\n \n \n Medical Product Quality Report_COVID-19 VACCINE issues_Up to 31March2021.pdf\n (1 MB)\n \n
\n \n \n \n \nMedical Product Quality Report - Covid 19 Issues Issue 9 for February 2021
\n \n\n \n \n \n \n \n \nMarch 2021 issue of the Medical Product Quality Report - COVID-19 vaccine. COVID-19 vaccines are vital interventions to help end the pandemic. However, with severe issues with equitable global access, falsified, diverted and substandard (especially degraded) vaccines are highly likely to become increasing global public health problems, leading to vulnerable communities thinking that they are protected when they are not. In order to facilitate our understanding of such reports and to inform interventions, we summarise reports in the public domain relevant to substandard and falsified (SF) COVID-19 vaccines since the start of the pandemic.
\n \n\n \n\n \n \n issues_MarMedical Product Quality Report_COVID-19 VACCINE ch2021_V3.pdf\n (1 MB)\n \n
\n \n \n \n \n\n \n \n GlobalLiteratureonSFCovid19Vaccines23Feb2021_updated.pdf\n (980 KB)\n \n
\n \n \n \n \nMedical Product Quality Report_Covid-19 Issues_Issue 7 December 2020_Main text only_V1
\n \n\n \n \n \n \n \n \nMedical Product Quality Report_Covid-19 Issues_Issue 7 December 2020_Main text plus annexes_V1
\n \n\n \n \n \n \n \n \nMedical Product Quality Report_Covid-19 Issues_Issue 6 November 2020_Main text only_V1
\n \n\n \n \n \n \n \n \nMedical Product Quality Report_Covid-19 Issues_Issue 6 November 2020_Main text plus annexes_V1.
\n \n\n \n \n \n \n \n \nMedical Product Quality Report_Covid-19 Issues_Issue 5 October 2020_Main text plus annexes
\n \n\n \n \n \n \n \n \nMedical Product Quality Report_Covid-19 Issues_Issue 5 October 2020_Main text
\n \n\n \n\n \n \n Medical Product Quality Report_Covid-19 Issues_Issue 5 October 2020_Main text.pdf\n (626 KB)\n \n
\n \n \n \n \nMedical Product Quality Report_Covid-19 Issue 4 September September 2020_Main text without annexes
\n \n\n \n \n \n \n \n \nMedical Product Quality Report_Covid-19 Issue 4 September 2020_Main text plus annexes
\n \n\n \n \n \n \n \n \n